← 프로그램 목록
ADCPhase 3Recruiting

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Daiichi SankyoAstraZeneca·Enhertu™

비교

T-DXd(Daiichi Sankyo / AstraZeneca)은 Advanced Solid Tumor 표적 ADC로, Breast Cancer; HER2-positive Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting the human epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 65.8% (ClinicalTrials.gov NCT04494425). 차별점: novel type of targeted systemic therapy that is changing the current landscape of tumor treatment.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

Advanced Solid Tumor

Breast Cancer; HER2-positive Breast Cancer

Recruiting

Technology

구조모아 · Exatecan/DXd (TOP1)구조모아 · Maytansinoid/DM1

ADCs) are active in brain metastases, their role in primary cen

DM1) and trastuzumab deruxtecan (T-DXd) usi

linker enables a stable, high-DAR exatecan-based HER2 ADC with potent antitumor activi

novel type of targeted systemic therapy that is changing the current landscape of tumor treatment

Mechanism of Action

targeting the human epidermal growth factor receptor

payloads, ADCs facilitate precise tumor killing

HER2 expression

resistance to ADCs will hopefully help to inform treatment strategies using sequential ADCs in lung cancer and other malignancies

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 66건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · N/A · Phase 2 · Phase 1, Phase 2
  • Status: Recruiting · Not yet recruiting · Active, not recruiting
  • 주요 endpoint: Real World Time to Next Treatment (rwTTNT1) in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer · Type of Treatment Patterns in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer · Number of Physician-reported Safety Events of Interest in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer (T-DXd only) · Number of Participants Receiving Prophylactic and Reactive Treatment Management for Physician-reported Safety Events of Interest in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer (T-DXd only) · Real World Time to Permanent Treatment Discontinuation (rwTTD1) in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer
  • 등록된 결과: ORR 65.8%
  • 핵심: This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's ch…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

T-DXd은 어떤 치료제인가요?
T-DXd(Daiichi Sankyo / AstraZeneca)은 Advanced Solid Tumor 표적 ADC로, Breast Cancer; HER2-positive Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
T-DXd의 임상 단계는?
T-DXd의 현재 단계는 Phase 3입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.